addit
neuraminidas
inhibitor
drug
directli
target
viral
replic
number
adjunct
immunomodulatori
therapi
current
evalu
treatment
influenza
novel
treatment
focu
either
pathophysiolog
aspect
influenza
viru
infect
neutral
viru
antibodi
subject
review
cytokin
dysregul
observ
patient
sever
influenza
avian
influenza
pandem
influenza
viru
infect
role
immunomodulatori
therapi
unclear
due
lack
data
random
control
trial
rct
convalesc
plasma
appear
use
adjunct
therapi
treatment
infect
late
data
interpret
limit
case
report
studi
nonrandom
design
recent
rct
found
patient
sever
influenza
treat
hyperimmun
immunoglobulin
person
surviv
diseas
lower
peak
viral
load
lower
mortal
control
provid
treatment
begun
within
day
symptom
onset
efficaci
agent
potenti
immunomodul
effect
includ
intraven
immunoglobulin
nacetylcystein
acut
use
statin
macrolid
peroxisom
proliferatoractiv
receptor
agonist
celecoxib
mesalazin
role
plasmapheresi
hemoperfus
rescu
therapi
deserv
investig
feasibl
studi
rct
prospect
observ
studi
shown
system
corticosteroid
increas
morbid
eg
secondari
infect
mortal
influenza
articl
form
part
symposium
antivir
research
treatment
influenza
target
viru
host
ever
sinc
first
human
case
highli
pathogen
avian
influenza
describ
hong
kong
chan
viru
unexpectedli
reappear
peiri
et
al
remain
major
emerg
diseas
global
concern
case
fatal
rate
potenti
caus
anoth
pandem
hui
earli
novel
swineorigin
influenza
viru
first
identifi
mexico
unit
state
spread
within
week
intern
travel
pandem
bautista
et
al
prospect
observ
studi
hong
kong
adult
hospit
infect
show
signific
complic
mortal
even
though
patient
younger
season
influenza
antivir
treatment
oseltamivir
administ
within
h
ill
onset
improv
surviv
without
time
treatment
mortal
risk
higher
season
influenza
vs
respect
adjust
odd
ratio
ci
p
lee
et
al
respiratori
failur
major
complic
patient
hospit
sever
influenza
patient
progress
rapidli
acut
respiratori
distress
syndrom
ard
multiorgan
dysfunct
chan
peiri
et
al
bautista
et
al
hui
hui
et
al
lee
et
al
sever
cytokin
storm
mark
elev
interleukin
il
detect
patient
sever
influenza
infect
associ
high
viral
load
peiri
et
al
de
jong
et
al
cytokin
dysregul
also
observ
patient
influenza
higher
plasma
level
proinflammatori
solubl
tumor
necrosi
factor
detect
sever
infect
compar
mild
diseas
high
cytokin
level
correl
progress
pneumonia
lee
et
al
antivir
therapi
neuraminidas
inhibitor
nai
improv
clinic
outcom
administ
patient
hospit
season
influenza
lee
et
al
within
day
ill
onset
may
reduc
mortal
start
within
day
symptom
onset
age
group
influenza
adisasmito
et
al
howev
final
outcom
often
compromis
delay
patient
present
initi
therapi
articl
review
potenti
role
immunomodulatori
agent
adjunct
therapi
manag
patient
hospit
sever
influenza
first
discuss
treatment
evid
clinic
benefit
review
current
data
insuffici
prove
either
posit
neg
effect
conclud
summar
therapi
predominantli
associ
worsen
clinic
outcom
convalesc
plasma
therapi
use
plasma
patient
fulli
recov
infect
treat
infect
one
metaanalysi
review
report
influenza
pandem
suggest
earli
administr
convalesc
blood
product
reduc
risk
death
pneumonia
overal
mortal
reduc
ci
luke
et
al
passiv
immunotherapi
form
convalesc
plasma
administ
adjunct
treatment
favor
outcom
patient
china
sever
influenza
pneumonia
multiorgan
failur
respond
initi
highdos
nai
oseltamivir
zhou
et
al
anim
data
shown
administr
specif
antibodi
form
neutral
monoclon
antibodi
polyclon
sera
convalesc
postimmun
effect
treat
influenza
diseas
lu
et
al
hanson
et
al
evid
benefici
effect
immunoglobulin
therapi
obtain
recent
influenza
pandem
prospect
multicent
casecontrol
studi
n
hong
kong
show
convalesc
plasma
neutral
antibodi
titer
effect
reduc
mortal
respiratori
tract
viral
load
serum
cytokin
level
patient
sever
infect
requir
intens
care
support
hung
et
al
recent
random
control
trial
rct
patient
sever
infect
five
hospit
hong
kong
assess
valu
treatment
hyperimmun
intraven
gammaglobulin
hivig
prepar
plasma
person
recov
diseas
comparison
treatment
normal
ivig
manufactur
hung
et
al
patient
standard
antivir
therapi
requir
intens
care
support
random
receiv
hivig
n
ivig
n
hivig
group
significantli
lower
day
viral
load
multivari
analysi
patient
receiv
either
hivig
ivig
within
day
symptom
onset
found
hivig
treatment
factor
independ
reduc
mortal
ci
p
comment
provid
suitabl
donor
avail
passiv
immunotherapi
convalesc
plasma
hyperimmun
globulin
prepar
convalesc
plasma
potenti
option
treatment
sever
influenza
ivig
contain
concentr
globulin
prepar
made
pool
human
plasma
studi
analyz
prepandem
ivig
sera
kawasaki
diseas
patient
receiv
ivig
standard
treatment
autoimmun
vascul
antibodi
microneutr
hemagglutin
inhibit
investig
found
six
ivig
prepar
test
signific
level
crossreact
specif
antibodi
concentr
gdl
immunoglobulin
sera
kawasaki
diseas
patient
signific
increas
crossreactivespecif
antibodi
receiv
gkg
prepandem
ivig
data
suggest
potenti
role
adjunct
ivig
therapi
sever
influenza
especi
immunocompromis
patient
case
report
male
patient
ard
due
influenza
respond
initi
twicedaili
oseltamivir
dose
mg
describ
favor
outcom
follow
administr
ivig
chong
et
al
signific
neutral
activ
influenza
virus
observ
lot
human
ivig
manufactur
japan
kubotakoketsu
et
al
comment
data
suggest
evalu
antibodi
titer
may
provid
use
inform
ivig
may
use
immunomodul
new
influenza
viru
emerg
human
popul
howev
import
watch
thromboembol
complic
sar
patient
treat
ivig
report
thromboembol
diseas
despit
use
prophylact
lowmolecularweight
heparin
like
relat
increas
blood
viscos
lew
et
al
chong
et
al
umapathi
et
al
nacetylcystein
nac
modifi
form
amino
acid
cystein
antioxid
properti
product
reactiv
oxygen
speci
ro
propos
mechan
pulmonari
damag
caus
influenza
viru
infect
han
meydani
leukocyt
may
activ
prime
viru
infect
produc
ro
increas
xanthin
oxidas
level
found
influenza
virusinfect
lung
akaik
et
al
lung
epitheli
cell
may
also
sourc
ro
sinc
influenza
viru
infect
induc
oxid
stress
respons
cultur
airway
epitheli
cell
knobil
et
al
nac
shown
inhibit
product
proinflammatori
molecul
lung
epitheli
cell
infect
highli
pathogen
influenza
viru
geiler
et
al
highdos
nac
administ
mgkg
daili
continu
iv
infus
appear
effect
reduc
creactiv
protein
oxygen
requir
improv
clinic
outcom
previous
healthi
woman
present
sever
pneumonia
septic
shock
due
influenza
howev
interpret
efficaci
nac
limit
concomit
use
nai
oseltamivir
mg
twicedaili
comment
clinic
data
base
rct
indic
evalu
role
nac
manag
sever
influenza
polymyxin
bimmobil
fiber
column
first
introduc
japan
extracorpor
devic
use
polymyxinb
fix
hchloroacetamidemethyl
polystyrenederiv
fiber
remov
circul
endotoxin
reduc
variou
cytokin
direct
hemoperfus
takeda
et
al
girl
sever
influenza
initi
respond
inhal
dri
powder
nai
zanamivir
mg
twicedaili
hypercytokinemia
elev
ifnc
highmobl
group
success
reduc
column
hemoperfus
result
favor
clinic
outcom
takeda
et
al
comment
difficult
judg
effect
polymyxin
bimmobil
fiber
column
hemoperfus
due
concomit
use
oseltamivir
sivelestat
inhibitor
human
neutrophil
elastas
patient
therapeut
plasma
exchang
tpe
plasmapheresi
extracorpor
blood
purif
techniqu
design
remov
largemolecularweight
substanc
plasma
pediatr
case
seri
describ
three
children
age
year
sever
influenza
complic
ard
hemodynam
instabl
requir
invas
mechan
ventil
inhal
nitric
oxid
one
receiv
extracorpor
membran
oxygen
patel
et
al
tpe
provid
rescu
strategi
patient
three
exchang
mlkg
consecut
day
dramat
subsequ
reduct
blood
lactat
level
oxygen
requir
inotrop
support
pediatr
logist
organ
dysfunct
score
patient
surviv
good
function
recoveri
comment
case
seri
suggest
role
tpe
strategi
cytokin
attenu
sever
shock
acut
lung
injuri
relat
influenza
respons
tradit
therapi
howev
control
studi
larger
sampl
size
need
statin
competit
inhibitor
enzym
hmgcoa
reductas
base
experiment
evid
antiinflammatori
immunomodulatori
effect
eg
repress
induct
mhcii
ifnc
subsequ
tlymphocyt
activ
observ
studi
show
surviv
benefit
patient
receiv
statin
develop
bacteremia
sepsi
cap
statin
propos
play
role
prevent
treatment
pandem
influenza
fedson
balbc
mice
infect
influenza
viru
combin
g
statin
g
caffein
amelior
lung
damag
inhibit
viral
replic
appear
least
effect
oseltamivir
ribavirin
liu
et
al
howev
statincaffein
combin
seem
effect
administ
prevent
rather
treatment
find
provid
justif
research
novel
antivir
formul
liu
et
al
howev
murin
model
influenza
viru
infect
administr
rosuvastatin
effect
viral
clearanc
infect
mortal
radigan
et
al
epidemiolog
studi
patient
take
statin
develop
influenza
given
conflict
result
populationbas
cohort
studi
influenza
season
brett
et
al
studi
hospit
adult
state
usa
influenza
season
analyz
evalu
associ
receiv
statin
influenzarel
death
treatment
hospit
associ
protect
adjust
oddsofdeath
ci
follow
adjust
age
race
comorbid
diseas
influenza
vaccin
antivir
administr
vanderm
et
al
comment
current
data
rct
acut
use
statin
manag
sever
influenza
drug
rel
cheap
readili
avail
research
warrant
role
adjunct
therapi
anim
model
human
clinic
studi
macrolid
belong
class
organ
compound
contain
larg
lacton
ring
made
twelv
member
act
inhibit
protein
synthesi
produc
actinomycet
bacteria
genu
streptomyc
macrolid
antibiot
clarithromycin
azithromycin
known
possess
antiinflammatori
effect
immunomodulatori
properti
addit
antibacteri
action
zarogoulidi
et
al
evid
benefici
effect
seen
influenza
respiratori
syncyti
viru
rsv
rhinoviru
infect
cultur
human
tracheal
epitheli
cell
infect
influenza
viru
clarithromycin
treatment
reduc
viral
titer
cytokin
supernat
fluid
viral
rna
cell
suscept
influenza
viru
infect
yamaya
et
al
also
reduc
express
sialic
acid
tracheal
mucos
surfac
number
fluoresc
intens
acid
endosom
cell
viral
rnp
enter
cytoplasm
yamaya
et
al
vitro
data
show
clarithromycin
act
middl
late
stage
viral
replic
cycl
inhibit
progeni
influenza
viru
product
miyamoto
et
al
howev
rct
young
patient
japan
mild
season
influenza
receiv
earli
nai
therapi
addit
clarithromycin
result
better
outcom
apart
shorter
durat
cough
patient
without
cough
onset
pyrexia
ishii
et
al
respiratori
syncyti
viru
bronchiol
treatment
clarithromycin
benefici
effect
length
hospit
stay
durat
need
supplement
oxygen
need
beta
agonist
treatment
signific
decreas
plasma
eotaxin
level
week
treatment
readmiss
hospit
within
month
discharg
also
significantli
lower
clarithromycin
group
tahan
et
al
azithromycin
antirhinovir
activ
bronchial
epitheli
cell
infect
significantli
increas
interferon
interferonstimul
gene
mrna
express
protein
product
treatment
also
significantli
reduc
viral
replic
releas
gielen
et
al
mous
model
parainfluenza
bronchiol
azithromycin
attenu
acut
chronic
airway
inflamm
beigelman
et
al
comment
find
demonstr
antiinflammatori
effect
clarithromycin
azithromycin
relat
antivir
activ
data
base
rct
need
role
macrolid
patient
hospit
sever
influenza
ppar
agonist
group
medic
act
peroxisom
proliferatoractiv
receptor
apart
clinic
use
lipidlow
activ
evid
gemfibrozil
ppara
agonist
inhibit
product
proinflammatori
cytokin
surviv
balbc
mice
infect
influenza
viru
increas
vehicletr
mice
n
mice
given
gemfibrozil
intraperiton
mgkg
daili
n
day
follow
intranas
infect
budd
et
al
studi
examin
effect
system
corticosteroid
dexamethason
versu
pparc
agonist
pioglitazon
outcom
influenza
mice
expos
room
air
cigarett
smoke
day
inocul
viru
mimic
influenza
copd
smokeexpos
mice
note
exacerb
inflammatori
respons
follow
infect
dexamethason
treatment
reduc
mononuclear
cell
bronchoalveolar
lavag
bal
smokeexpos
virusinfect
mice
pioglitazon
reduc
mononuclear
cell
neutrophil
bal
increas
peripher
cell
bauer
et
al
anoth
studi
mice
challeng
virul
influenza
virus
includ
current
circul
avian
strain
increas
select
accumul
particular
dendrit
cell
dc
subset
tnfinosproduc
tip
dc
note
airway
mice
pneumonia
aldridg
et
al
tipdc
appear
requir
prolifer
influenzaspecif
cell
infect
lung
block
recruit
mice
decreas
number
effector
reduc
viru
clearanc
howev
investig
found
treatment
pparc
agonist
pioglitazon
reduc
tipdc
traffick
conclud
might
moder
potenti
lethal
consequ
excess
tipdc
recruit
without
abrog
cell
expans
compromis
viru
control
aldridg
et
al
comment
studi
suggest
altern
antiinflammatori
drug
pparc
agonist
explor
treatment
sever
viral
infect
influenza
effect
delay
nai
therapi
combin
immunomodulatori
agent
assess
balbc
mice
challeng
highli
pathogen
influenza
viru
zheng
et
al
drug
treatment
deliber
initi
h
viral
challeng
imit
reallif
scenario
surviv
rate
surviv
time
improv
group
receiv
combin
zanamivir
celecoxib
mesalazin
compar
zanamivir
alon
significantli
higher
level
cell
less
pulmonari
inflamm
also
note
group
receiv
tripl
therapi
zanamivir
alon
reduc
viral
load
without
signific
effect
lung
inflamm
mortal
celecoxib
well
known
inhibitor
mesalazin
inhibit
lipoxygenas
cox
pathway
lead
reduct
proinflammatori
cytokin
eicosanoid
therefor
deactiv
inflammatori
cell
macrophag
neutrophil
mesalazin
also
inhibit
nfjb
activ
promot
phosphatid
acid
synthesi
inhibit
stimulatori
effect
ceramid
apoptosi
zheng
et
al
comment
clinic
studi
need
therapeut
role
immunomodul
agent
sever
influenza
data
sever
observ
studi
shown
system
corticosteroid
therapi
associ
higher
risk
death
increas
rate
nosocomi
pneumonia
increas
risk
develop
critic
diseas
patient
hospit
influenza
especi
initi
oseltamivir
day
ill
receiv
nai
therapi
prospect
observ
studi
adult
hospit
season
influenza
hong
kong
show
system
corticosteroid
administ
acut
exacerb
either
chronic
obstruct
pulmonari
diseas
copd
asthma
independ
risk
factor
adjust
ci
associ
delay
viral
clearanc
beyond
first
week
ill
lee
et
al
han
et
al
contrast
retrospect
review
japanes
patient
nation
hospit
receiv
nai
mostli
within
day
ill
onset
show
administr
system
corticosteroid
pneumonia
acut
wheez
associ
advers
outcom
kudo
et
al
sar
outbreak
provid
import
lesson
regard
widespread
use
system
corticosteroid
relat
complic
may
implic
manag
sever
influenza
system
corticosteroid
wide
use
sar
patient
progress
respiratori
failur
base
evid
bronchiol
obliteran
organ
pneumonia
lee
et
al
tse
et
al
one
uncontrol
studi
show
favor
clinic
respons
reduct
inflammatori
cytokin
howev
studi
hospit
patient
random
receiv
either
earli
intraven
hydrocortison
normal
salin
plasma
level
sarscov
rna
consider
higher
week
ill
among
receiv
hydrocortison
suggest
system
corticosteroid
might
prolong
viremia
invas
fungal
infect
fatal
outcom
occur
patient
sar
wang
et
al
lat
et
al
receiv
system
corticosteroid
ard
wherea
higher
rate
ventilatorassoci
pneumonia
sar
period
observ
sar
outbreak
yap
et
al
osteonecrosi
occur
patient
receiv
system
corticosteroid
sar
griffith
et
al
hong
du
risk
cumul
dose
g
versu
g
cumul
prednisolon
equival
dose
griffith
et
al
although
numer
rct
suggest
system
corticosteroid
improv
clinic
outcom
patient
hospit
communityacquir
pneumonia
cap
nie
et
al
must
point
studi
includ
predominantli
cap
case
bacteri
receiv
appropri
antibiot
therapi
favor
result
therefor
gener
cap
viral
lee
hui
comment
data
call
caution
use
system
corticosteroid
manag
patient
sever
viral
pneumonia
includ
influenza
especi
delay
lack
effect
antivir
therapi
howev
lowdos
system
corticosteroid
may
consid
treatment
refractori
septic
shock
relat
sever
influenza
recommend
world
health
organ
bautista
et
al
convalesc
plasma
appear
use
adjunct
therapi
influenza
infect
limit
avail
time
administr
recent
interpret
efficaci
convalesc
plasma
tabl
gener
comment
relat
adjunct
therapi
immunomodulatori
agent
treatment
sever
influenza
summari
find
agent
evid
patient
benefit
passiv
immunotherapi
convalesc
plasma
hyperimmun
immunoglobulin
case
report
nonrandom
studi
rct
shown
benefit
given
earli
diseas
cours
efficaci
may
limit
avail
donor
time
administr
ivig
may
neutral
activ
influenza
virus
caution
thromboembol
side
effect
nacetylcystein
data
limit
case
report
relat
influenza
vitro
test
ppar
agonist
data
limit
anim
studi
macrolid
favor
vitro
data
limit
human
data
influenza
cheap
readili
avail
conflict
epidemiolog
data
outcom
influenza
chronic
user
data
acut
use
statin
sever
influenza
data
limit
anim
studi
may
play
role
rescu
therapi
need
data
case
seri
may
play
role
rescu
therapi
need
data
case
report
system
corticosteroid
risk
mortal
morbid
eg
secondari
infect
increas
administr
system
corticosteroid
sever
influenza
especi
delay
lack
effect
antivir
therapi
system
corticosteroid
may
prolong
viremia
limit
data
base
case
report
studi
nonrandom
design
howev
newli
publish
rct
shown
patient
sever
influenza
receiv
hyperimmuneivig
lower
viral
load
lower
risk
death
treatment
begun
within
day
symptom
onset
evalu
antibodi
titer
may
provid
use
inform
ivig
may
use
immunomodul
new
influenza
viru
emerg
human
popul
anim
experi
detail
human
observ
studi
feasibl
rct
need
evalu
efficaci
agent
potenti
immunomodulatori
effect
acut
use
statin
nac
macrolid
ppar
agonist
celecoxib
mesalazin
particular
role
plasmapheresi
hemoperfus
rescu
therapi
requir
investig
tabl
system
corticosteroid
may
increas
risk
mortal
morbid
includ
hospit
length
stay
secondari
bacteri
fungal
infect
patient
sever
influenza
especi
delay
lack
effect
antivir
therapi
